Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: Judy who wrote (17475)	3/19/1998 1:16:00 PM
From: Leman	Respond to of 50167

LIFC news Thursday March 19, 12:20 pm Eastern Time Company Press Release LifeCell Announces Study Finds Alloderm(R) Equivalent to "Gold Standard" in Reconstructive Burn Surgery Shriners Burn Institute Study Being Presented at Thirteenth Annual Meeting of American Burn Association LifeCell Corporation (Nasdaq:LIFC - news) today announced that a study demonstrating the benefits of AlloDerm(R) acellular dermal grafts in reconstructive burn surgery is being presented at the Thirteenth Annual Meeting of the American Burn Association held in Chicago March 18-21. The study indicated that AlloDerm was equivalent to the current ''gold standard'' in reconstructive burn procedures, thereby providing superior clinical results through the reduction of donor site trauma. The study by Robert L. Sheridan, M.D., Ramsey J. Choucair, M.D., M.B. Donelan, M.D., and others at the Shriners Burn Institute in Boston is titled ''One Year Follow-Up of Acellular Allodermis in Burn Surgery'' and describes the treatment of six burn patients ranging in age from three to ten years old. The children were burned on average over 68 percent of their bodies, resulting in limited areas of unburned skin (donor sites) to transplant to treat the burn area. Ten sites on patients were grafted with AlloDerm covered by a thin autograft, a thin layer of skin taken from a donor site on the patient. Control sites were grafted with the current ''gold standard'' for burn treatment, a standard thickness autograft. Nine of the sites were reconstructive procedures and one was an acute burn excision. The study determined using the Vancouver Scar Score that sites treated with AlloDerm and the control sites were substantially equivalent at twelve months post-surgery. ''The Shriners study demonstrates that the burn wound has an equivalent appearance using AlloDerm,'' commented Stephen Livesey, M.D., Ph.D., LifeCell's executive vice president and chief science officer. ''Prior to the availability of AlloDerm, the use of standard autografts alone has been the ''gold standard'' for burn treatment but results in trauma and potential complications at the donor site, including infection and scarring. The Shriners study indicates that AlloDerm allows the surgeon to use thinner autografts, resulting in a superior outcome for the patient by reducing the donor site trauma and related complications.'' Preliminary results of the study at three months following surgery were identical to the twelve month results and were previously published in the Nov./Dec. issue of the Journal of Burn Care & Rehabilitation in an article titled ''Acellular Allogenic Dermis Does Not Hinder Initial Engraftment in Burn Wound Resurfacing and Reconstruction.'' LifeCell Corporation is a bioengineering company engaged in the development and commercialization of tissue regeneration and cell preservation products. LifeCell's first commercial product, AlloDerm(R) acellular dermal graft, is used in reconstructive plastic, dental and burn surgery. In addition to AlloDerm grafts, the Company's current tissue graft development plans include the LifeCell(R) heart valve, vascular grafts and nerve connective tissue. LifeCell's product development programs also include ThromboSol(tm), a formulation for extending the shelf life of transfusable platelets. For additional information about the Company, visit LifeCell's web site at lifecell.com. Certain of the statements contained in this news release are forward-looking statements. While these statements reflect the Company's current beliefs, they are subject to uncertainties and risks that could cause actual results to differ materially. These factors include, but are not limited to, the uncertainty of clinical trials, the uncertainty of patent protection, the demand for the Company's products and services, economic and competitive conditions and products and other risks detailed in the Company's Annual Report on Form 10-K for the year ended Dec. 31, 1997.

To: Judy who wrote (17475)	3/20/1998 2:12:00 AM
From: Philip H. Lee	Read Replies (1) \| Respond to of 50167

IP telephony projections: Excerpted from netinsider.com "We're starting to see it pick up this year, in 1998. Certainly I'm looking by 2001, 2002, for somewhere between 15 to 30 percent of all voice traffic to be IP-based." "I think around the world today it is, in fact, the major carriers, in Europe especially, that are providing leadership by rolling out the first wave of IP-based voice services." -- Jeff Pulver pulver.com Major pure plays: quote.yahoo.com IDT Corp. (IDTC) - perhaps the most successful co. providing Internet telephony to consumers. Dialogic (DLGC) - according to press release, "the leading provider of scalable, standards-based Internet Protocol (IP) telephony platforms." Inter-tel (INTL) - Vocal'Net IP Telephony Gateway named a Product of the Year by CTI Magazine. Natural Microsystems (NMSS) - delivers "the industry's most scalable H.323-Compliant IP telephony platform" according to press release. NetSpeak (NSPK) - Wall St. favorite, wireless IP telephony deal with Motorola, partnership with Bay Networks. Vocaltec (VOCLF) - markets client/server solution for the ITSP market, including the Internet Phone(R) 5 and VocalTec Telephony Gateway(tm) server. CTI = Computer Telephony Integration ITSP = Internet Telephony Service Provider Some smaller players: Franklin Telecom (FTEL) Digitcom (DGIV) Linkon (LKON) Voxware (VOXW) White Pine (WPNE) Philip Disclaimer: Do your own research. Invest at your own risk. Information provided for discussion purposes only and not to be construed as investment advice. Information not guaranteed to be accurate.